Objective: Survivors of severe critical illness frequently develop substantial and persistent physical complications, including muscle weakness, impaired physical function, and decreased health-related quality of life. Our objective was to determine the longitudinal epidemiology of muscle weakness, physical function, and health-related quality of life and their associations with critical illness and ICU exposures. Design: A multisite prospective study with longitudinal follow-up at 3, 6, 12, and 24 months after acute lung injury. Setting: Thirteen ICUs from four academic teaching hospitals. Patients: Two hundred twenty-two survivors of acute lung injury. Interventions: None. Measurements and Main Results: At each time point, patients underwent standardized clinical evaluations of extremity, hand grip, and respiratory muscle strength; anthropometrics (height, weight, mid-arm circumference, and triceps skin fold thickness); 6-minute walk distance, and the Medical Outcomes Short-Form 36 health-related quality of life survey. During their hospitalization, survivors also had detailed daily evaluation of critical illness and related treatment variables. Over one third of survivors had objective evidence of muscle weakness at hospital discharge, with most improving within 12 months. This weakness was associated with substantial impairments in physical function and healthrelated quality of life that persisted at 24 months. The duration of bed rest during critical illness was consistently associated with
weakness throughout 24-month follow-up. The cumulative dose of systematic corticosteroids and use of neuromuscular blockers in the ICU were not associated with weakness. Conclusions: Muscle weakness is common after acute lung injury, usually recovering within 12 months. This weakness is associated with substantial impairments in physical function and healthrelated quality of life that continue beyond 24 months. These results provide valuable prognostic information regarding physical recovery after acute lung injury. Evidence-based methods to reduce the duration of bed rest during critical illness may be important for improving these long-term impairments. (Crit Care Med 2014; 42:849-859) Key Words: adult; cohort study; intensive care units; muscle weakness; recovery of function; respiratory distress syndrome; survivors O ver recent decades, decreasing mortality from critical illness have contributed to an increasing number of ICU survivors (1) (2) (3) (4) (5) and a greater need to understand survivors' post-ICU morbidities and recovery process. Neuromuscular abnormalities associated with critical illness are of particular interest given their high prevalence among patients with severe or prolonged critical illness (6) . Hence, there is interest in understanding the persistence of muscle weakness after ICU discharge and its longitudinal associations with critical illness risk factors and long-term impairments in physical function and health-related quality of life (HRQOL) (7) (8) (9) (10) (11) (12) .
Acute lung injury (ALI) is an archetype of severe critical illness (13) . Studies of ALI have yielded many important insights into post-ICU patient outcomes (1) (2) (3) (4) (5) 13) , including recognition that nearly all ALI survivors report substantial impairment in physical function and HRQOL functional status up to 5 years after ICU discharge despite minimal pulmonary morbidity (6, 9, 10, 12) . Whether these impairments correlate longitudinally with objective measures of muscle strength, and the associations of muscle weakness with ICU-related risk factors have not been comprehensively evaluated. Thus, we conducted a 2-year prospective follow-up study of ALI survivors to evaluate these issues.
METHODS

Study Design
Mechanically ventilated patients with ALI (14) were consecutively enrolled in the prospective Improving Care of ALI Patients (ICAP) cohort study between October 2004 and October 2007 from 13 ICUs at four hospitals in Baltimore, MD (13, 15) . To avoid including patients with primary neurologic disease or head injury, neurologic specialty ICUs were excluded from enrollment. Key exclusion criteria were as follows: 1) preexisting illness with a life expectancy of less than 6 months; 2) preexisting cognitive impairment or communication/language barriers; 3) no fixed address; 4) transfer to a study site ICU with preexisting ALI of greater than 24 hours duration; 5) greater than 5 days of mechanical ventilation before ALI; 6) greater than 4 days between ALI diagnosis and enrollment; 7) prior lung resection; and 8) a physician order for no escalation of ICU care (e.g., no vasopressors or hemodialysis) at the time of study eligibility.
Informed consent was obtained after patients regained capacity, typically around the time of hospital discharge (16) . In-person patient evaluations occurred at 3, 6, 12, and 24 months after ALI onset. The institutional review boards of all study sites approved this research.
Muscle Strength and Outcome Measures
At each follow-up interval, patients were evaluated in a research clinic, their home, or healthcare facility, including standardized evaluation of extremity (17) , hand grip (18) and respiratory muscle strength (maximum inspiratory pressure [MIP]) (19) ; anthropometrics (weight, body mass index [based on measured height], mid-arm circumference, triceps skin fold thickness, and arm muscle area) (20); 6-minute walk distance (6MWD) (21, 22) ; and HRQOL (using Medical Outcomes Short-Form 36 Health Survey [SF-36]) (23) . As in prior research, we estimated pre-ALI HRQOL retrospectively from patients and focused on the Physical Function Subscale (PFS) of SF-36 (range, 0-100, with higher score indicating better HRQOL) for this evaluation.
Peripheral muscle strength assessment was performed with standardized manual muscle testing (MMT), scored using the 6-point Medical Research Council (MRC) ordinal scale (range, 0 [paralysis] to 5 [normal strength]) (17, 24) . Peripheral strength was evaluated bilaterally for 13 muscle groups (total of 26 groups) and corresponding MRC scores were summed to yield a composite score of overall strength (range, 0-130) (25) . To aid in comparison with prior studies, an abbreviated composite MRC score (range, 0-60), calculated from a subset of three upper and three lower extremity muscle groups, was the primary measure of muscle strength in this evaluation (7, (26) (27) (28) (29) (30) (31) . As done in prior studies, clinically significant muscle weakness (referred to hereafter as "ICU-acquired weakness" [ICUAW]) was defined as less than 80% of the maximum score (i.e., mean MRC score < 4) (7, 31) . Extensive training and quality assurance evaluation were undertaken to ensure high interrater reliability of these assessments (median intraclass correlation coefficient, 0.99; 95% CI, 0.97-1.00) (32) .
When calculating the composite MRC score, if data were missing for one muscle group (e.g., due to a radial arterial catheter limiting testing of one wrist), the MRC score for the contralateral muscle group was substituted given that ICUAW affects left and right sides similarly (7) . If muscle strength data were missing bilaterally for a muscle group, it was imputed using the average score from the other muscle groups for purposes of calculating the composite MRC score (7, 32) .
ICU Exposures and Confounders
We evaluated for associations of the outcome measures with a number of patient and ICU variables, selected a priori based on prior studies (33) . We measured cumulative systematic corticosteroid use-our primary exposure-on a daily basis and converted to hydrocortisone-equivalents (34) . The following baseline patient characteristics were evaluated: age, sex, admission location (e.g., home, rehabilitation facility, and nursing home), and the Functional Comorbidity Index (35 [42] of -4 or -5); delirium (proportion of noncomatose ICU study days with a positive Confusion Assessment Method for the ICU assessment) (43) ; and receipt of physical therapy in the ICU (ever vs never, days from ALI onset until physical therapy initiation).
Statistical Analysis
Variables were modeled as continuous when appropriate (based on inspection of exposure-outcome plots during exploratory data analysis); otherwise, they were dichotomized at clinically relevant thresholds. We assessed bivariate associations of study variables and ICUAW using the Wilcoxon rank-sum and Fisher exact tests, as appropriate. Since the abbreviated composite MRC score has an upper bound of 60 (no weakness) and a skewed distribution with scores clustering within 10 points of this upper bound, the score transformed by subtracting it from 60 (such that 0 corresponds to no weakness) so that its distribution could be modeled by a gamma function (R 2 = 0.99 at baseline). Thus, our primary analysis used the transformed MRC score at each time point as the outcome and a generalized linear regression model, assuming a gamma distribution and log link function, with regression coefficients interpreted as the relative decrease from maximum MRC score for each unit change in the exposure variable. For secondary analyses in which the distribution of the outcome variable was less skewed (e.g., MIP), we modeled the outcome using a normal distribution; for regression of binary outcomes, we used a binomial distribution. All multivariable analyses were evaluated for multicollinearity using variance inflation factors (17, 44) and included the exposure and confounder variables described previously. Due to collinearity, we removed maximum SOFA score (collinear with APACHE II score) and the duration of mechanical ventilation and ICU length of stay (collinear with duration of bed rest) from our primary analysis. Based on prior literature (18, 45), we tested for interaction between blood glucose and cumulative corticosteroid dose. We assessed for goodness of fit by visual inspection of deviance residuals (including plots against predicted values) and for influence by assessment of Cook's distance. When influential points were identified, we evaluated alternative models with influence points removed to evaluate robustness of results, with our primary analysis retaining all data points. Statistical significance was defined as p value less than 0.05 (two-sided). All analyses were conducted using STATA 11.0 (Stata Corporation, College Station, TX).
RESULTS
Patient Baseline Characteristics and Follow-Up Assessments
The ICAP study enrolled 520 ALI patients with high severity of illness (Table 1) , of whom 274 (53%) survived to hospital discharge. Of 224 survivors (82%) who consented and were eligible for follow-up, 222 (99%) had muscle strength evaluated at least once during study follow-up and were followed longitudinally ( Fig. 1) , with two excluded from this evaluation due to persistent vegetative state and bilateral above-knee amputations. Compared with those who died in hospital or who did not participate in follow-up, participants were younger and less severely ill; had longer ICU stay and mechanical ventilation duration; but were more likely to receive physical therapy and had less sepsis, renal failure, delirium, coma, corticosteroid exposure, and reduced nutritional intake. Importantly, survivors continued to experience substantial mortality following ICU and hospital discharge.
Epidemiology of Anthropometric, Muscle Strength, and Physical Function Assessments
The proportion of patients with ICUAW declined over time: 36% at hospital discharge, 22% at 3 months post-ALI, 15% at 6 months, 14% at 12 months, and 9% at 24 months. Corresponding 24-month trajectories of physical outcome measures are shown in Figure 2 . Specifically, the abbreviated composite MMT score increased from a median (interquartile range [IQR]) of 50 (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) at hospital discharge to 57 (53) (54) (55) (56) (57) (58) (59) (60) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) , respectively. Arm muscle area was significantly associated with decreased hand grip strength at all four time points (R 2 = 0.97) and with both MMT (at all time points) and ICUAW (at 6 and 12 mo) (Fig. 3) . Arm muscle area was not associated with the other outcome measures at more than one time point during follow-up.
Risk Factors for the Development of ICUAW
Patient and critical illness-related risk factors' associations with ICUAW were similar whether ICUAW was measured using the abbreviated (range, 0-60) or full (range, 0-130) composite MMT scores (data not shown). As all three measures of muscle strength (MMT, MIP, and grip) were highly correlated, we focused on risk factor associations with our primary outcome, the abbreviated MMT composite score, to allow comparability with previous studies.
In multivariable regression analysis of all patient and critical illness-related risk factors, duration of bed rest was the single risk factor most consistently associated with muscle weakness throughout longitudinal follow-up ( Table 2) . After adjusting for all other risk factors, muscle strength was 3-11% lower for every additional day of bed rest. Other variables significantly associated with peripheral muscle weakness at hospital discharge included older age and proportion of ICU days alert (i.e., RASS, -1, 0, or +1), but these associations were no longer significant at 3 months post-ALI.
In multivariable regression analysis, cumulative corticosteroid dose in the ICU was not significantly associated with peripheral muscle weakness at discharge or any time in the first year after ALI (Table 2) . Similarly, there was no significant association between corticosteroids and all other physical outcome measures any time point (data not shown). At all time points, there was no association between increased mean ICU blood glucose (defined as > 150 mg/dL) and muscle weakness (Table 2) , and no significant interaction between increased blood glucose and corticosteroid dose. These findings were not affected by a differential effect of steroids on patient survival since cumulative corticosteroid dose was not significantly associated with hospital mortality after adjustment for potential confounders (as listed in Table 2 ).
Association of ICUAW With Other Outcome Measures
The association between ICUAW and the other outcome measures is summarized in Figure 4 . At all follow-up time points, patients with versus without ICUAW had significantly lower hand grip strength (p < 0.01) and SF-36 PFS (p ≤ 0.001) and significantly lower MIP (p < 0.02) and 6MWD (p ≤ 0.01) at all time points after 3 months post-ALI.
DISCUSSION
In this multisite prospective cohort study of 222 ALI survivors, over one third of participants were discharged from the hospital with objective evidence of ICUAW, with most improving within 12 months. This muscle weakness was associated with substantial impairments in physical function and HRQOL that persisted at 24 months. These results provide valuable prognostic information for patients and their caregivers regarding longer-term physical recovery after ALI. Based on comprehensive evaluation of patient and critical illness-related risk factors for muscle weakness, we found that the cumulative dose of systemic corticosteroids and use of neuromuscular blockers in the ICU were not independently associated with muscle weakness at any time point, while the duration of bed rest was the only factor consistently associated with weakness throughout 24-month follow-up. Hence, evidence-based methods to reduce the duration of bed rest may be the most important target intervention for ameliorating these common and substantial long-term physical complications experienced by ALI survivors. These data demonstrate that objectively measured ICUAW has an important association with the substantial and persistent impairments in physical function and HRQOL observed in prior studies of ICU survivors (7-12, 19, 31, 46) . The relative plateau in recovery of the physical outcome measures at 12 months post-ALI observed in our data is consistent with prior studies (9, 10, 47, 48) . Given that muscle strength recovers more quickly than physical function and HRQOL, ALI survivors' persistent limitations in physical function and HRQOL are unlikely to be due to ICUAW alone, with many other factors (e.g., cognitive and mental health morbidity, home environment, and caregiver support) likely playing an important role in determining physical limitations and disability (21, 22, 49-51) .
Furthermore, the muscle strength testing employed in our study does not reliably evaluate other neuromuscular factors that may have an important impact on physical function, such as pain and endurance. Thus, evaluating functional outcomes longitudinally may be especially important in future studies on the long-term effects of ICUAW.
Survivors of ALI and other critical illnesses often have severe muscle wasting with loss 18% of their body weight during ICU admission (9, 52) . Immobility and enforced bed rest are modifiable risk factors during critical illness that can result in substantial disuse atrophy and accelerated muscle breakdown (17, 24, 53) , contributing to the development of ICUAW (25, 54) . Our study demonstrated significant associations of arm muscle area with strength measures during the 24-month follow-up. Furthermore, the duration of bed rest in the ICU was the single risk factor that was consistently associated with muscle weakness throughout the entire follow-up, with each additional day of bed rest having up to an 11% relative decrease in muscle strength at 24 months post-ALI (Table 2) . Physical therapy, aimed at reducing bed rest via early rehabilitation interventions, was provided to approximately half of survivors while in the ICU and started, in those patients, at a median of 10 days after ICU admission, as there were no trials demonstrating the safety, feasibility, and benefits of early rehabilitation interventions in the ICU during the time period of patient enrollment (7, (26) (27) (28) (29) (30) (31) 54) . New trials evaluating the longer-term impact of early ICU rehabilitation interventions are needed to demonstrate if these physical complications can be ameliorated.
A prospective observational study reported that exposure to corticosteroids was the strongest risk factor for ICUAW upon awakening after 7 days of mechanical ventilation (OR, 14.9; 95% CI, 3.2-69.8), but there was no significant association between ICUAW and cumulative corticosteroid dose or corticosteroid duration (7) . However, the role of systemic corticosteroids in the development of ICUAW continues to be debated, with a number of subsequent studies and systematic reviews (7, 26, 27, 31, 32, 45, 55-60 ) failing to demonstrate a consistent association between corticosteroids and ICUAW. We found no significant association between ICUAW and corticosteroid use in the ICU in our cohort, whether corticosteroids were modeled as any exposure, cumulative dose, or treatment duration (data not shown). In contrast to a previous study (7, 9) , we found no association between corticosteroids and 6MWD, or with any other physical outcome, at any point in follow-up. Interestingly, a recent study reported that hyperglycemia may partially mediate the deleterious effects of corticosteroids on the neuromuscular system (7, 32, 45) ; however, we found no association between mean blood glucose levels and ICUAW, nor any evidence that the effect of corticosteroids on ICUAW was modified by blood glucose level. Our results support the notion that the current patterns of use of neuromuscular blockers are unlikely to be a significant independent risk factor for ICUAW (33, 61) . Finally, our results regarding nutritional intake in the ICU are consistent with prospective follow-up studies of the NHLBI ARDS Network's Early vs. Delayed Enteral Nutrition trial that demonstrated no effect of initial trophic versus full enteral feeding on 6-and 12-month measures of muscle strength and physical function (62, 63) .
Our results also suggest that future evaluations of post-ICU muscle strength may be simplified. Specifically, we evaluated three different objective measures of muscle strength and found that all measures were highly correlated. Especially for large-scale, multisite studies, hand grip dynamometry may be simpler, more cost-effective, and efficient to perform than MMT, which requires rigorous training and ongoing quality assurance to ensure high interrater reliability (32, 34, 64, 65) . However, greater evaluation, in future studies and in other populations of ICU survivors, is required to confirm this finding.
There are several potential limitations of this study. First, as with all observational studies, due to a lack of randomization, we cannot assess causality of the associations reported. Second, we employed a clinical definition for ICUAW and did not measure mechanisms of muscle weakness (e.g., nerve conduction studies, electromyography, and muscle and nerve biopsies). This approach is most clinically feasible across ICUs and ensures comparability of our findings with previous studies (7, (26) (27) (28) (29) (30) (31) . Furthermore, we evaluated strength using 26 bilateral muscle groups using trained assessors with high interrater reliability (32) . However, MMT requires appropriate patient motivation and engagement with the evaluation and also has a ceiling effect compared to other measurement approaches (66) (67) (68) . Third, given the acute and unpredictable nature of critical illness, we could not obtain prospective baseline measurements of muscle strength and physical function, requiring the use of population norms for presentation of results. Fourth, we did not account for effects of posthospitalization interventions (e.g., physical rehabilitation and repeat hospitalizations)
on the physical outcome measures that may have affected the recovery process. Fifth, the association between corticosteroids and ICUAW could have been impacted by an effect of corticosteroids on ICU mortality (i.e., survivor bias) (69). However, there was no independent association of corticosteroids with Total ICU dose of narcotic (per 500 mg morphine-equivalent) For patients who received dialysis in the ICU. Values in bold represent statistically significant and consistent associations of exposure variables with muscle weakness (defined as those associations with p < 0.05 for at least 3 of the 5 time points evaluated).
ICU mortality in our cohort to raise this potential bias. Finally, all the study sites were teaching hospitals, which may limit the generalizability of the findings. However, four hospitals with 13 ICUs participated, representing a heterogeneous group of patients and variability in the medical care provided, which may aid in generalizability.
In conclusion, survivors of ALI have substantial physical morbidity after ICU discharge, including impairments in muscle strength, physical function, and HRQOL. Recovery of muscle strength (evaluated by MMT) generally occurs within 12 months after ALI, but muscle weakness contributes to significant impairments in physical function and HRQOL that persist to 24 months post-ALI. The results of our study provide valuable prognostic information for patients and their caregivers regarding the physical recovery after ALI. Based on comprehensive evaluation of patient and critical illness-related risk factors for muscle weakness, the duration of bed rest during critical illness was the only factor consistently associated with weakness throughout 24-month follow-up. Hence, evidencebased methods to reduce bed rest (e.g., early physical and occupational therapy) during critical illness may be the most important target interventions for ameliorating the common and substantial long-term physical complications experienced by ALI survivors. 
